Abstract Background Belzutifan, a hypoxia-inducible factor-2α (HIF-2α) inhibitor, has demonstrated efficacy in advanced clear-cell renal cell carcinoma (ccRCC) in patients previously received immunotherapy (IO) and anti-angiogenics. However, comorbidities pose a challenge in cancer management and often limit inclusion...
Ali Hajj Ali, Liliana Ascione, R. Nawfal et al.· The Oncologist· 0 citations
Abstract Background Previous retrospective work found an association between earlier immune-checkpoint inhibitors (ICI) infusion times and survival outcomes in renal cell carcinoma (RCC). A recent randomized trial in non-small cell lung cancer (NSCLC) also reported benefit, however, a recent analysis of several randomi...
P. Barrios, Mustafa Saleh, Liliana Ascione et al.· The Oncologist· 0 citations
Abstract Background Nivolumab plus ipilimumab (NIVO+IPI) combination therapy is a first-line standard in metastatic renal cell carcinoma (mRCC). Despite durable responses in some patients, over 20% develop primary progressive disease (PPD) at first restaging imaging. In this study, we evaluated clinical factors associa...
É. Ibrahim, Wan-Ling Xie, R. El Hajj Chehade et al.· The Oncologist· 0 citations
Survition analysis revealed that high expression of both DSG2 and NPNT is significantly associated with poorer overall survival in ChRCC patients, underscoring their potential as prognostic biomarkers.
Tie-Gang Han, Clara Steiner, Steven Safi et al.· The Oncologist· 0 citations
Abstract Background Hypoxia signaling is a key driver of renal cell carcinoma (RCC) and is mediated by HIF-dependent transcription. ARNT (HIF-1β) is an essential HIF binding partner, but its expression and clinical relevance in RCC are poorly defined. With ARNT inhibitors in development, characterizing ARNT expression...
Yu-Wei Chen, S. Nazari, A. Elliott et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.